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Background: Compounds that can act as agonists for toll-like receptors (TLRs) may be promising candidates for
the development of drugs against infectious diseases and cancer. The present study aimed to characterize the
immunomodulatory effects of P-MAPA on TLRs in vitro and in vivo, as well as to investigate its potential as adjuvant
therapy in infectious diseases and cancer.
Methods: For these purposes, the activity of P-MAPA on TLRs was assayed in vitro through NF-κB activation in
HEK293 cells expressing a given TLR, and using an in vivo animal model for bladder cancer (BC). The antimicrobial
activity of P-MAPA was tested against Mycobacterium tuberculosis (TB) in vitro in an MIC assay, and in vivo using an
aerosol infection model of murine tuberculosis. Antitumor effects of P-MAPA were tested in an animal model with
experimentally induced BC. Moxifloxacin (MXF) and Bacillus Calmette-Guerin (BCG) were used as positive controls in
the animal models.
Results: The results showed that P-MAPA, administered alone or in combination with MXF, induced significant
responses in vivo against TB. In contrast, the compound did not show antimicrobial activity in vitro. P-MAPA
showed a significant stimulatory effect on human TLR2 and TLR4 in vitro. In BC, TLR2, TLR4 and p53 protein levels
were significantly higher in the P-MAPA group than in the BCG group. The most common histopathological
changes in each group were papillary carcinoma in BC group, low-grade intraepithelial neoplasia in BCG group and
simple hyperplasia in P-MAPA group. Concerning the toxicological analysis performed during BC treatment, P-MAPA
did not show evidence for hepatotoxicity and nephrotoxicity.
Conclusions: In conclusion, P-MAPA acted as TLR ligand in vitro and improved the immunological status in BC,
increasing TLR2 and TLR4 protein levels. P-MAPA immunotherapy was more effective in restoring p53 and TLRs
reactivities and showed significantly greater antitumor activity than BCG. The activation of TLRs and p53 may
provide a hypothetical mechanism for the therapeutic effects in both cancer and infectious diseases. Taken
together data obtained will encourage the further investigation of P-MAPA as a potential candidate for the
treatment of cancer and infectious diseases.
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Immunotherapy represents an approach for the treat-
ment of infectious diseases and cancer [1-3]. Effective
immunotherapy for chronic infectious diseases or cancer
requires the use of appropriate target antigens, the
optimization of the interaction between the antigenic
peptide, the antigen-presenting cell (APC) and the T cell
and the simultaneous blockade of negative regulatory
mechanisms that impede immunotherapeutic effects
[1,3]. In cancer, besides the impairment of the immuno-
logical status associated with the main disease, several
therapies can often cause additional immunosuppression
creating the conditions for the emergence of infections
[1-4]. In this scenario, compounds which can act in the
immune system such as new vaccines, vaccine adjuvants
and biological response modifiers are considered poten-
tial candidates for the treatment of these diseases or
conditions. Compounds that target the TLRs may repre-
sent starting points for the development of new drugs,
since the TLRs are increasingly implicated in the patho-
genesis of some diseases [5,6]. In fact, recent advances in
TLR-related research have also shown the therapeutic
properties of these receptors against several diseases,
including infectious diseases and cancer [7-9]. Conse-
quently, compounds that mimic pathogen associated
molecular patterns and activate immune cells via TLRs
are candidate drugs being developed to treat several dis-
eases and to be used as vaccine adjuvants. TLRs are trans-
membrane proteins that recognize pathogen-associated
molecular patterns as well as endogenous damage-
associated molecular patterns and elicit pathogen-induced
and noninfectious inflammatory responses [10,11].TLRs
were initially detected only on immune cells, but recent
studies demonstrate that tumor cells express functional
TLRs and that TLR signaling can promote opposite out-
comes: tumor growth and immune evasion or apoptosis
and cell cycle arrest [12-14].
Compounds from microbial sources as well as bacter-
ial strains themselves, such as Bacillus Calmette-Guerin
(BCG), are used as therapeutic tools in the treatment of
some types of cancer, including urothelial cancer [15,16].
BCG is a live, attenuated strain of Mycobacterium bovis
used widely for tuberculosis (TB) prophylaxis. However,
the exact mechanism by which BCG exerts its antitumor
effect remains unknown. The treatment of choice for BC
is transurethral resection (TUR) and adjuvant therapy
with BCG [15-17]. The objective of intravesical BCG
therapy is to reduce the risk of recurrence or eradicate
carcinoma in situ in patients if complete resection it is
not possible [18,19]. BCG administered as a control in
the cancer model admittedly acted as TLR2 and TLR4
agonist, since the cell wall of mycobacteria contains cer-
tain antigens which are recognized by local macrophages
and immature dendritic cells (DC) [20]. Peptidoglycan isan important mycobacterial cell wall component, which
is covalently linked to arabinogalactan and mycolic acids
[21,22]. In a series of experiments, different research
studies have demonstrated that this mycobacterial cell
wall component stimulated TLR2 and TLR4 responses
in immature DC cells [21,22]. Although intravesical
BCG immunotherapy treatment can reduce the risk of
recurrence and progression of BC, its use is limited by
the adverse effect profile and intolerance that occurs in
20 % of patients, from mild and self-limiting side effects
to potentially life-threatening complications, such as
systemic BCG infection [23,24].
With respect to infectious diseases, tuberculosis is far
from being controlled or eradicated. On the contrary, it
is becoming resistant to existing drugs, including most
antimicrobial drugs. Mycobacterium tuberculosis, the
bacterium that causes pulmonary TB remains a major
global health problem, infecting nearly one-third of the
world’s population and killing at least 3 million people
every year [4]. The occurrence of drug-resistant strains
of Mycobacterium tuberculosis emphasizes the urgent
need for developing new drugs, including those drugs
capable of boosting the body’s immune response.
Immunotherapy through the use of compounds that act
as agonists for TLRs, can represent a valuable approach
to infectious diseases and cancer, when used in com-
bination with existing therapies.
P-MAPA can be an immunomodulatory drug candi-
date. The compound’s ability to fight cancer and infec-
tious diseases was detected in earlier studies using animal
models [25-27]. P-MAPA is an acronym for Protein Aggre-
gate Magnesium-Ammonium Phospholinoleate-Palmitoleate
Anhydride, a proteinaceous aggregate of ammonium
and magnesium phospholinoleate-palmitoleate anhyd-
ride, with immunomodulatory properties produced by
fermentation of Aspergillus oryzae, under development by
Farmabrasilis, a non-profit research network [25,28,29].
The compound is a nonlinear biopolymer with molecular
mass of 320 kDa. The main components of P-MAPA are
Mg2+, NH4+, phosphate, linoleic acid, palmitoleic acid and
protein [25,29-31]. The P-MAPA immunomodulator was
originally intended for cancer treatment, and has effect-
ively demonstrated antitumor activity in several animal
models including cancer by chemical inducers/promoters
[27]. P-MAPA induces immunodulatory effects, including
increased cytokine production, mainly interferon-gamma
(IFN-γ) and interleukin 2 (IL-2), and stimulates nitric
oxide release by macrophages [25,29-31]. These findings
expanded the potential therapeutic applications of the
compound, suggesting that P-MAPA, like other com-
pounds with immunomodulatory properties, can fight a
wide range of infections caused by intracellular pathogens
[25,31]. The compound did not show significant toxicity
in the preclinical phase when assessed in in vitro cell
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tration of 120 μg/ml) and in vivo acute and chronic tox-
icity models using Swiss mice (single dose toxicity, oral, at
30 g/kg,), Wistar rats (12-week multiple-dose toxicity,
injected subcutaneously, at 1, 10 and 100 mg/kg), and
monkeys (Cebus apella; 4-week multiple dose toxicity,
injected intramuscularly at 5,10 and 30 mg/kg) [28,31].
Moreover, the use of P-MAPA in clinical trial phase I did
not show any signs of adverse drug reaction at dosages
of 5 mg/square meter, injected intramuscularly, 3 times a
week, for 6 weeks [29].
Thus, the present study was aimed to characterize
the effects of P-MAPA on TLRs in vitro and in vivo,
as well as to assess its potential as adjuvant therapy for
infectious diseases and cancer. Regarding its action
against cancer, the efficacy of P-MAPA was compared
versus BCG in the BC mouse model. And regarding its
action against infectious diseases, the in vivo efficacy
of P-MAPA was compared alone and co-administered




The P-MAPA samples showed a significant stimulatory
effect on human TLR2 at a 5 μg/mL concentration cor-
responding approximately to 30 % of the control ligand
(Figure 1). Furthermore, P-MAPA samples showed a sig-
nificant stimulatory effect on human TLR2 and TLR4
at 50 μg/mL corresponding approximately to 88 %
and 32 % of the control ligands, respectively (Figure 1).
P-MAPA did not show a significant stimulatory effect on
human TLR3, TLR5, TLR7, TLR8 and TLR9 (Figure 1).
In Vitro Antimycobacterial Activity of P-MAPA
P-MAPA was initially tested using the Rezasurin MIC
assay (single point procedure) against H37Rv strain and
did not show any antimycobacterial activity in vitro
at a concentration of 10 μg/mL (Table 1). Consequently,
no further testing of P-MAPA was performed with
standard MIC assays (doses range between 0 ug/ml to
0.078 ug/ml) using colorimetric methods. Also, negative
and sterility control groups did not show any antimyco-
bacterial activity (Table 1).
Rifampin (0.006 μg/mL) and isoniazid (0.06 μg/mL) posi-
tive controls showed antimycobacterial activity (Table 1).
In Vivo Antimycobacterial Activity of P-MAPA and MXF
The P-MAPA, MXF and MXF+P-MAPA treatments
yielded 0.94, 1.80 and 1.75 log10 CFU in lung, respect-
ively, conferring protection to the lung (Table 2). These
results showed a statistically significant improvement in
the lung (p< 0.001) in comparison with untreated con-
trols (Table 2).In an initial plating spleen, P-MAPA treatment did not
show a statistically significant protective effect on the spleen
(p> 0.05) (Table 2). Because of the low bacterial load in the
spleens at the initial plating experiment of several animals
in the drug treatment groups, the stored undiluted spleen
homogenate was re-plated undiluted to increase sen-
sitivity. On replating, the P-MAPA treatment yielded
1.03 log10 CFU in the spleen, which showed a statistically
significant improvement in spleen status (p< 0.05) when
compared to the untreated controls (Table 2).
The combined treatment of MXF+P-MAPA resulted
in 1.93 log10 CFU of protection in the 1
st plating of
spleen, which was statistically significant (p< 0.001)
compared to untreated controls (Table 2). On replating,
the MXF+P-MAPA treatment showed 2.65 log10 CFU
reduction in the spleen compared to untreated controls
(Table 2).
There was no statistically significant difference between
MXF administered alone and MXF+P-MAPA (p> 0.05)
in either lung or spleen (Table 2). Upon replating of
the spleen, there was also no statistically significant differ-
ence between MXF administered alone and MXF+P-
MAPA (p> 0.05) (Table 2).
Histopathological Analysis in Bladder Cancer
The urinary tract in the CT group showed no structural
changes (Figures 2a and 3a). However, the urinary tract in
the MNU group showed significant histopathological
changes such as hydronephrosis and hydroureter (Figures 2b
and 2c); papillary carcinoma of the urinary bladder (pTa)
and carcinoma in situ (pTis) in 60.0 % and 30.0 % of the
animals, respectively (Figures 2b, 2c, 3b and 3e).
Papillary hyperplasia (40.0 %) and low-grade intrae-
pithelial neoplasia (30.0 %) were the more frequent
histopathological changes in the urinary bladder in the
BCG group (Figures 3c and 3e). Also, the urinary tract
in the BCG group showed macroscopic changes such as:
cystic lesions in the kidneys, hydroureter, thickening of
the wall of the urinary bladder and papillary lesions
(Figure 2d).
The macroscopic features of the urinary tract in the
P-MAPA group were similar to those found in the CT
group (Figure 2e). In the urinary bladder, the more fre-
quent histopathological changes in the P-MAPA group
were flat hyperplasia (60.0 %) and papillary hyperplasia
(20.0 %) (Figures 3d and 3e).
The occurrence of urinary calculi and macroscopic
haematuria was only observed in the MNU and BCG
groups, being absent in the P-MAPA group (Figure 2f ).
Western Blotting Analysis of TLR2, TLR4 and p53
in Bladder Cancer
The highest TLR4 and TLR2 protein levels were found in
the P-MAPA groups compared to the other experimental
Figure1 Human TLR ligand screening.
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higher in the BCG group than in the CT and MNU
groups (Figure 4).
The p53 protein level was significantly higher in the
P-MAPA groups than in the BCG and CT groups. Fur-
thermore, this level was significantly higher in the BCG
and CT groups when compared to the MNU group
(Figure 4).
Toxicological Analysis in Bladder Cancer
The ALT and AST levels did not show any statistical dif-
ference among the four experimental groups (Table 3).
Creatinine and urea levels were significantly higher in
the MNU group compared to BCG and P-MAPA groups,
which did not show statistical differences (Table 3). TheTable 1 MICs of Rifampin and Isoniazid as antimicrobial
agents and P-MAPA for Mycobacterium tuberculosis







Isoniazid 0.06alkaline phosphatase activity was significantly higher in
the MNU group compared to the other experimental
groups (Table 3).
Discussion and conclusions
Compounds that act as agonist for TLRs, or in
other words, compounds or molecules that bind to and
activate TLRs are the subject of intensive research and
development for the treatment of infectious diseases
and cancer. In this regard, the present studies detail a
series of in vitro and animal models and demonstrate
that the immunomodulator P-MAPA exhibits significant
antimycobacterial and antitumor activity. TLR activa-
tion facilitates and instructs the development of adaptive
immune responses by increasing the levels of expression
of co-stimulatory molecules such as CD80 and CD86
on DC, allowing DC to more effectively activate T cells
[21,32].
An important aspect of the induced cytokine produc-
tion is the differentiation of T cells either into Th1 or
Th2 subsets, which will guide the pattern of adaptive re-
sponse launched by the host against the pathogen. For
instance, human monocyte-derived DC stimulated with
lipopeptide from Mycobacterium tuberculosis secretes
IL-12 over IL-10, skewing the host's adaptive immune
response toward a Th1 pattern, characterized by a cel-
lular, cytotoxic T cell response [33].
Table 2 Plating and Replating of lung and spleen for P-MAPA, MXF and MXF+P-MAPA antimycobacterial activities
Compounds Tissues














Untreated Ctrl 4.66 - 0.11 6/6 4.29 - 0.12 6/6 3.34 - 0.18 6/6
MXF 2.86a 1.80 0.13 6/6 2.80a 1.49 0.23 6/6 1.38a 1.96 0.29 5/6
P-MAPA 3.72a 0.94 0.10 6/6 3.74 0.55 0.12 6/6 2.31a 1.03 0.12 6/6
MXF+ P-MAPA 2.91a 1.75 0.14 6/6 2.36a 1.93 0.32 6/6 0.69a 2.65 0.32 4/6
n=Number of mice with CFU/total number of mice at sacrifice; MXF =Moxifloxacin; SEM= standard error of the mean; log10 prot = log10 CFU of protection; Letter
a: significantly different from Untreated Ctrl group.
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to recognize Mycobacterium tuberculosis-associated mo-
lecular patterns and mediate the secretion of cytokines
and other antibacterial effector molecules [34,35]. The
immune system recognizes pathogen-associated mole-
cular patterns (PAMPs) such as the bacteria’s outer cellFigure 2a - 2e Histopathological analysis in urinary tract of the anima
and (e) the urinary tract showed normal features. (b) Lesion widespread in
lesions (arrows) in the kidneys; hydroureter (open arrowheads); thickening
arrowhead). (c) Intravesical pappillary lesions (arrow); hydroureter. (d) Cyst
thickening of the wall of the urinary bladder and papillary lesions (solid ar
- right ureter, UB - urinary bladder. Figure 2f: The animals from the MNU a
group showed no macroscopic haematuria.wall composition of peptidoglycan, mycolic acids, lipo-
mannan, and lipoarabinomannan [36]. PAMPs stimulate
immune recognition receptors such as toll-like receptors
(TLR) [37,38]. In vitro studies have delineated these
mechanisms, providing evidence that TLR2 and TLR4
are stimulated by interactions with Mycobacterium cellls from CT (a), MNU (b, c), BCG (d) and P-MAPA (e) groups. In (a)
different points of the urinary tract: hydronephrosis the and papillary
of the wall the of the urinary bladder and pappillary lesions (solid
ic lesions (arrow) in the kidney; hydroureter (open arrowhead);
rowhead). a - e: LK - left kidney, LU - left ureter, RK - right kidney, RU
nd BCG group showed macroscopic haematuria (arrow). P-MAPA
Figure 3 Photomicrographs of the urinary bladder from Control (a), MNU (b), BCG (c) and P-MAPA (d) groups. (a) Normal urothelium; (b)
Papillary carcinoma; (c) Carcinoma in situ; (d) Flat hyperplasia. a - d: Ur - urothelium. (e) Percentage of histopathological changes of the urinary
bladder of rats from CT, MNU, BCG and P-MAPA groups.
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phages, and production of IFN-γ [39,40]. Other studies
suggest that TLRs variants may contribute to human
susceptibility to tuberculosis disease [41]. Recent studies
in animal models also suggested that TLR, mainly TLR-
2 and TLR-4 may play a protective role in host defense
against lung infection by Mycobacterium tuberculosis
[42,43].
The protective immunity against Mycobacterium tuber-
culosis has been ascribed to CD4+ T cell-mediated immu-
nity [42,43]. The breakdown of immune responses
designed to contain the infection can result in reactivationand replication of the bacilli, with necrosis and damage to
lung tissue [44,45]. An efficient immune response against
the intracellular pathogen Mycobacterium tuberculosis is
critically dependent on rapid detection of the invading
pathogen by the innate immune system and the coordi-
nated activation of the adaptive immune response [45].
An effective response against Mycobacterium tuberculosis
was demonstrated in vivo in the present study. P-MAPA
did not show any direct in vitro antimicrobial activity.
In vivo P-MAPA alone or combined with MXF did
not show synergistic and/or antagonic effects; however
P-MAPA induced a significant antimicrobial response
Figure 4 Representative Western Blotting and semiquantitative determination for TLR2, TLR4 and p53 protiens of the urinary bladder
extracts in the four experimental groups. The protein levels were identified in the blots. β-Actin was used as the endogenous control. Data
were expressed as the mean ± standard deviation (n = 5).
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required to investigate whether this result is observed
with the use of P-MAPA combined with other TB drugs
(such as rifampin or isoniazid), or whether this is a
MXF-specific effect. This finding could be relevant for
the use of P-MAPA as candidate to be evaluated in anti-
tubercular treatments, with the aim of reducing the
doses of antimicrobials or shortening the period required
for administration of such drugs.Ayari et al. [46] have recently shown that TLRs are
expressed in normal urothelium and BC. The role of
TLRs in cancer is a matter of debate because conflicting
data argue that TLRs are negative or positive regulators
of cancer [47,48]. Different authors demonstrated that
TLRs help tumour cells evade immune system response
[12,49] while others showed that TLRs expression on
tumour cells might drive them to apoptosis or other
types of cell death [50-52]. Activated TLRs on cancer
Table 3 Toxicological and Biochemical Biomarkers for Control, MNU, BCG and P-MAPA groups
Parameters Control MNU BCG P-MAPA
(n = 10) (n = 10) (n = 10) (n = 10)
ALT (U/L) 49.23 ± 1.61 46.03 ± 0.63 46.30 ± 3.60 51.61 ± 7.07
AST (U/L) 189.72 ± 28.74 133.05 ± 2.29 201.61± 23.84 208.38 ± 31.34
Alkaline Phosfatase (U/L) 42.97 ± 0.87a 128.11 ± 8.21 38.88 ± 3.51a 40.56 ± 3.93a
Urea (mg/dL) 55.45 ± 3.90a 163.09 ± 14.14 60.52 ± 5.90a 57.32 ± 7.16a
Creatinine (mg/dL) 1.18 ± 0.26a 10.33 ± 0.10 1.22 ± 0.25a 1.94 ± 1.24a
Data expressed as mean ± SEM, p< 0.05; Letter a: significantly different from MNU group. MNU= n-methyl-n-nitrosourea; BCG= Bacillus Calmette-Guerin.
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apoptotic activity and resistance to host immune
responses [49,53,54]. Some TLRs have been connected
with tumor progression and invasion as after TLR
stimulation they can increase the expression of matrix
metalloproteinases, up regulate different cytokines and
chemokines or other inflammatory factors [54-56]. Mati-
jevic et al. [57] and Matijevic & Pavelic [58] investigated
the difference between primary tumour and metastasis
based on TLR3 level and found a huge difference
between FaDu and Detroit 562 cell lines, which were of
the same origin (pharynx), but FaDu was primary and
Detroit 562 metastatic carcinoma. The same authors
reported on the dual role of TLR3 in pharynx metastatic
cell line (Detroit 562); on the one hand TLR3 activation
drove cells to apoptosis, while on the other its stimula-
tion contributed to tumor progression by altering the
expression of tumor promoting genes (PLAUR, RORB)
and enhancing the cell migration potential. In addition,
these authors showed that TLR3 signaling pathway was
functional in another metastatic cancer cell line (SW620)
suggesting TLR3 might be important in the process of
tumor metastasis.
In this context, the administration of TLR agonists
was also reported to exert strong antineoplastic effects
against established tumors in mice and humans
[12,14,59]. TLR activation may also cause tumor regres-
sion by increasing vascular permeability and through the
recruitment of leukocytes, which determines tumor cell
lysis by natural killer (NK) and cytotoxic T cells [59].
Accordingly, one of the most promising effects of TLR
stimulation by specific agonists in cancer therapy is the
activation of the adaptive immune system [14,60].
The contradictory evidence that TLR promotes car-
cinogenesis, whereas in others it exerts antitumor
effects, could be explained by the different intensity and
nature of the inflammatory response [48]. In fact,
chronic inflammatory processes are milder than acute
inflammatory responses, which are aimed at inducing
pathogen clearance. In most cases, cancer-associated in-
flammation is similar to chronic inflammation, including
the production of factors that stimulate tissue repair and
cancer cell survival and proliferation [48]. However,if the inflammatory response develops into acute inflam-
mation, an immune effector mechanism is activated, and
cancer regression takes place [48,61]. Among the differ-
ent elements that control neoplastic processes, a major
role is attributed to members of the chemokine super-
family. Chemokines expressed by tumor cells and by
host cells play a critical role in determining the fate of
the developing tumor by regulating the migration of dif-
ferent leukocyte subtypes [48,62]. The relative propor-
tion of each defense cell type (macrophages, T cells, NK
cells, dendritic cells, or other leukocyte subtypes) within
the tumor largely dictates the immune profile at the
tumor site; local production of numerous inflammatory
mediators is crucial for the recruitment and activation of
leukocytes in addition to macrophages and mast cells
[48,63]. In particular, CD8 T cells and some types of
innate immune cells, such as NK cells, can protect
against experimental tumor growth [48,64].
Thus, the present study showed that P-MAPA
increased significantly TLR2, TLR4 and p53 protein
levels. In addition, it was demonstrated that this immu-
nomodulator was more effective in the treatment of BC
compared to BCG. These results were correlated with
the ability of P-MAPA to act as TLR ligand, mainly for
TLR2 and TLR4. The increased TRL2 and TLR4 levels
were fundamental for antitumor immunotherapy of BC.
Furthermore, the present study demonstrated that the
MNU animal model could lead to BC, besides kidney
failure and increased alkaline phosphatase activity. Proc-
tor et al. [65] demonstrated that increased alkaline phos-
phatase activity was associated with the presence of
cancer and could be associated with mortality.
This MNU-Citrate animal model has particular advan-
tages for the experimental analysis of complete carcino-
genesis, since the carcinogen can be administered
directly in quantifiable pulse doses, via intravesical instil-
lation [66,67]. In addition, this autochthonous BC model
includes low cost, reproducibility and an immunocom-
petent host, which is important, for example, when
studying intravesical BCG treatment of BC [26,67,68].
Bladders treated with intravesical MNU-Citrate develop
progressive neoplastic changes and tumours become
progressively less differentiated with time. These lesions
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(CIS) and papillary carcinoma to large bulky muscle
invasive tumours that completely fill the bladder lumen,
obstruct the ureters and kill the animal [26,67,69]. Fur-
thermore, the MNU-Citrate animal model is similar to
human urothelial carcinogenesis; it involves the effect of
environmental agents (carcinogen, smoking) in a genet-
ically susceptible substrate (Fisher 344 rats) [26]. Intra-
vesical instillation of fractionated doses of carcinogen
and promoter provided a more controlled cancer model
than those using carcinogens in the diet or drinking
water. Added to its effectiveness (100 % of induction),
low cost (not dependent on high-cost technologies) and
short period of induction, it is in a position of superior-
ity considering other available models, being a useful
model for further studies [26].
The ability of intravesically administered BCG to exert
an antineoplastic effect on BC is widely accepted and
serves as the basis for its clinical use [70,71]. This agent
induces a complex systemic immune response com-
prising humoral and cellular components [72]. Recent
studies have demonstrated that polymorph nuclear
neutrophils (PMN) migrating to the bladder after BCG
instillation release large amounts of TNF-related apoptosis-
inducing ligand (TRAIL), along with cytokines that
recruit other immune cells, suggesting that PMN play a
key role in the antitumor response to BCG therapy
[15,73]. BCG intravesical immunotherapy induces a well-
described T-lymphocyte predominant inflammatory infil-
trate in the bladder wall and induces cytokines in the
bladder and in urine [74]. These cytokines have anti-
tumor and anti-angiogenic activity, and they share com-
mon regulatory pathways [74]. A number of prior reports
documented a direct antiproliferative effect of BCG on
urothelial carcinoma cells [75]. Potential mechanisms
contributing to this biological effect include cell cycle
arrest and/or apoptosis. DiPaola & Lattime [71] demon-
strated that BCG induced signaling alters the susceptibil-
ity of the cell to an apoptotic insult. Thus, the consensus
is that BCG serves as an immune potentiator of lympho-
cytes, namely an adjuvant, via the maturation of DC
[22]. It appears that the effects in bladder cancer are
local only. There is no protection against the develop-
ment of tumors in areas where there is no BCG contact
(e.g., the distal ureter and prostatic urethra).
BCG use is limited in BC by treatment failure, adverse
effects and intolerance that occur in over two-thirds of
all patients and consist largely of irritative voiding symp-
toms including haematuria, dysuria and urgency [19].
Even major complications and death related to treatment
have been described [76]. In the BC studies presented
here, the results demonstrated that P-MAPA immuno-
therapy was more effective in restoring normal mor-
phological features and alkaline phosphatase activitycompared to BCG. Concerning the toxicological analysis,
the present results showed that both P-MAPA and BCG
treatments did not show hepatotoxicity and nephrotox-
icity compared to MNU group, which showed higher
creatinine and urea serum levels; and indicating that
high molecular weight of P-MAPA and BCG probably
hinder local diffusion into the bladder wall thereby
preventing systemic toxicity. Although BCG did not
cause systemic toxicity, this immunotherapy led to
intense local adverse effects such as haematuria com-
pared to P-MAPA treatment, which was absent.
In addition, P-MAPA also increased the p53 protein
level in the BC cancer model. The p53 gene and protein
expression levels both play a critical role in the regula-
tion of the normal cell cycle, cell cycle arrest, and apop-
totic response [77-79]. Alterations in the p53 protein,
leading to a loss of its tumor suppressor function, have
been reported previously by some authors [79,80]. The
p53 gene status has been examined in a number of
malignancies, including cancers of bladder, breast, lung,
ovary and colorectal cancer [79-83]. Studies of promoter
response element sequences targeted by the p53 master
regulatory transcription factor suggest a general role for
this DNA damage and stress-responsive regulator in the
control of human TLR gene expression [84]. Most of
the TLR genes respond to p53 via canonical as well as
noncanonical promoter binding sites [84]. Expression of
all TLR genes, TLR1 to TLR10, in blood lymphocytes
and alveolar macrophages from healthy volunteers
can be induced by DNA metabolic stressors [84]. Also,
Menendez et al. [84] demonstrated that all TLR
genes showed responses to DNA damage, and most were
p53-mediated.
In conclusion, the presented results showed that P-MAPA
was able to improve, and/or re-establish the immuno-
competence when the immune system was impaired, by
cancer and possibly in infectious diseases, resulting in
remarkable therapeutic effects. The P-MAPA therapy
showed stimulatory effect on TLRs and p53 that cor-
related with the decrease of cancer state. Furthermore,
P-MAPA induced significant responses in vivo against
TB. Thus, these results pointed out that P-MAPA hypo-
thetically acted in a common control mechanism for
both infectious diseases and cancer, which involved
TLRs and p53 signaling pathway. Finally, the low toxicity
of P-MAPA combined with its significant antimycobac-
terial and antitumor activities warrant its development as
a potential candidate for adjuvant treatment of cancer
and infectious diseases.
Perspectives
This work shows the toll-like stimulating properties of
P-MAPA in vitro and in vivo. The immunomodulator
P-MAPA alone showed significant efficacy against
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when administered at 5 mg/kg. P-MAPA did not show
any direct antibactericidal activity in vitro against
Mycobacterium tuberculosis (H37Rv).Taken together
data obtained suggest an immunotherapeutic effect of
the compound against tuberculosis in vivo. Stimulation
on TLRs is a feasible possibility to explain this effect,
to be explored in additional studies.
Since the P-MAPA has not shown antagonic effects on
the antimicrobial action of MFX in vivo, we aim to assay
the compound together with other antitubercular com-
pounds at lower doses of antimicrobials, or by shorten-
ing the period of time administration of such medicines.
The low in vivo toxicity of P-MAPA is another benefit of
the compound. Experiments on P-MAPA activity on
Cytochrome P-450 are under way which may provide
additional data on the potential for interaction with
other compounds.
In a series of experiments evaluating the potential of
P-MAPA in cancer models, the toll-like ligand properties
of P-MAPA were tested in vitro and subsequently the
use of the compound alone and compared with BCG in
an animal model when the immune system is impaired
by carcinogen and with BC.
The results indicate the stimulatory effect of P-MAPA
and BCG on TLR2, TLR4 and p53 in vivo. More import-
antly, the results correlated with a re-establishment of
immunocompetence and a significant therapeutic effect
in the treated animals was seen for both compounds in
relation to controls. Thus, looking ahead, the data pro-
vides instigating insights for a possible use of P-MAPA
as adjuvant with BCG or other therapies aiming to boost
its effects against cancer.
An important question to be answered concerns the
determination of the optimal dose for the immunomo-
dulator P-MAPA to be used alone or in combinations
with other drugs. Like other biological therapies, the
in vivo response to P-MAPA may be not linear and
hence lower doses or single dose schedules may achieve
improved responses in vivo. Previous results from
experiments concerning the use of P-MAPA in the
Punta toro virus (PTV) infected mice model suggests
that single dose schedules may work better than
repeated doses [25]. Further studies are being planned to
elucidate this question using animal models for the
study of infectious diseases and cancer.
The modification of antioxidant enzyme activity that
plays an essential role in cellular defense mechanisms
against oxygen toxicity has been observed in various
cancers. The importance of antioxidants and reactive
oxygen species (ROS) in carcinogenesis is considered in
experimental studies in vivo. The Nuclear Factor-κB
(NF-κB) signaling pathway plays an important role in
inflammation, cancer and stress responses. Some NF-κBtargets, such as the Cytochrome p450, CYP1B1, antioxi-
dants and, mainly TLRs, have been implicated in modu-
lating cellular redox potential. Thus, studies concerning
the TLR and its signaling pathways associated with anti-
oxidants and ROS are being planned to investigate
the role of P-MAPA as an antioxidant agent in vitro
and in vivo. These studies may provide useful data




P-MAPA assay procedure: Human TLR Ligand Screening
The effect of P-MAPA on TLRs was performed through
NF-κB activation in HEK293 cells expressing a given
TLR (InvivoGen, San Diego, CA, USA). The secreted
alkaline phosphatase (SEAP) reporter is under the con-
trol of a promoter inducible by the transcription factor
NF-κB. This reporter gene allowed the monitoring of
signaling through the TLR, based on the activation of
NF-κB. The activity of P-MAPA (Farmabrasilis, Campi-
nas, SP, Brazil) in a screening test was assessed in seven
different human TLRs (TLR2, 3, 4, 5, 7, 8 and 9). The
Control ligands for TLRs were: TLR2: HKLM (heat-
killed Listeria monocytogenes) at 108 cells/ml; TLR3:
Poly(I:C) at 1 μg/mL; TLR4: E. coli K12 LPS at 100 ng/
ml; TLR5: S. typhimurium flagellin at 100 ng/ml; TLR7:
CL097 at 1 μg/mL; TLR8: CL075 at 1 μg/mL; TLR9:
CpG ODN 2006 at 1 μg/mL; NF-κB Control cells: TNFα
at 100 ng/ml (InvivoGen, San Diego, CA, USA). The
P-MAPA (5 mg) was diluted with 1 mL of dimethyl
sulfoxide (DMSO) for a stock concentration of 5 mg/mL.
The P-MAPA samples were tested at final concentration
of 50, 5 and 0.5 μg/mL and compared to control ligands.
This step was performed in duplicate (InvivoGen, San
Diego, CA, USA).
In a 96-well plate (200 μL total volume) containing the
50,000 cells/well, 20 μL of P-MAPA sample or the posi-
tive control ligands were added to the wells. The media
was added to the wells, which was designed for the
detection of NF-κB induced SEAP expression. After a
16–20 h incubation the optical density (OD) was read at
650 nm on a Beckman Coulter AD 340 C Absorbance
Detector (InvivoGen, San Diego, CA, USA).
Resazurin MIC (Minimum Inhibitory Concentration) Assay
and Single Point Concentration Procedure
The antimycobacterial activity of P-MAPA was tested
at a concentration of 10 μg/ml against Mycobacterium
tuberculosis H37Rv (H37Rv), obtained from Colorado
State University, Fort Collins, CO (SRI International,
Menlo Park, CA, USA). Upon receipt, test P-MAPA was
logged into the inventory spreadsheet and placed in a
−20 °C freezer [85]. On the day of the experiment, one
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to achieve a stock concentration of 3.2 mg/ml. Initially,
P-MAPA compound was screened by means of in vitro
tests (resazurin MIC assay) using a single concentration
of 10 ug/ml of the compound (single point concentra-
tion procedure) against M.tuberculosis (H37Rv strain).
Positive controls such as Isoniazid (INH) and Rifampin
were used for comparative purposes. If compounds
are active below 10 μg/ml, they are further tested in a
MIC assay at 8 concentrations in a dose range between
10 ug/ml to 0.078 ug/ml. [85]. H37Rv was grown in
Middlebrook 7 H9 broth medium (7 H9 medium) sup-
plemented with 0.2 % (v/v) glycerol, 10 % (v/v) ADC
(albumin, dextrose, catalase), and 0.05 % (v/v) Tween 80.
The bacteria were inoculated in 50 ml of 7 H9 medium
in 1 liter roller bottles that were placed on a roller bottle
apparatus in an ambient 37 °C incubator. When the
cells reach an OD600 of 0.150 (equivalent to ~1.5 x
107 CFU/ml), they were diluted 200-fold in 7 H9
medium. After, 20 μl of the 3.2 mg/ml test P-MAPA
were added to a 96-well microtiter plate. Also, 2-fold
dilutions were made by the addition of 20 μl of diluent.
Each dilution was further diluted 1:10 in sterile water
(10 μl of dilution to 90 μl of sterile water). The add-
itional 10-fold dilution in water was required when
DMSO was used as solvent to minimize toxicity to the
bacteria. Each dilution (6.25 μl) was transferred to dupli-
cate 96-well test plates. After, 93.75 μl of the cell suspen-
sion (~ 104 bacteria) in 7 H9 medium were added to the
test plates (SRI International, Menlo Park, CA, USA).
Positive, negative, sterility and resazurin controls were
tested. Positive controls included rifampicin and isonia-
zid; Negative controls included cell culture with solvent
and water, or cell culture only; Sterility controls included
media only or media with solvent and water. Resazurin
control included one plate containing the diluted P-MAPA
with resazurin only (SRI International, Menlo Park,
CA, USA).
The 96 well test plates were incubated in an ambient
37 °C incubator for 6 days. After the 6 days of incubation,
5 μl of a 0.05 % sterile resazurin solution were added to
each well of the 96-well plate. The plates were placed
in an ambient 37 °C incubator for 2 days. After the 2 day
incubation, visual evaluation and fluorimetric read-out
were performed. The results were expressed as μg/ml
(visual evaluation) and as IC50 (fluorimetric read-out).
The single point concentration procedure was the same
as the one used for the above described MIC procedure,
but only a two-fold dilution was made in order to reduce
the stock concentration to 1.6 mg/ml. An additional 1:10
dilution was made in water which further reduces the
stock solution to 0.16 mg/mL. Addition of 6.25 μl of the
1:10 dilution to the wells in a final volume of 100 μl will
give rise to a concentration equivalent to 10 μg/ml.Only compounds that showed activity less than 10 μg/
ml concentration were submitted to fluorimetric read-
out analysis.
In Vivo Assays
P-MAPA and Moxifloxacin (MXF) Activities against
Mycobacterium tuberculosis (Erdman Strain)
Female C57BL/6 mice, 6 and 8 weeks old, were obtained
from the Charles River Laboratories (Wilmington, MA).
These animals were housed up to 5 animals per cage in
HEPA-filtered racks (Thoren Caging Systems Inc. Hazle-
ton, PA) in certified animal biosafety level 3 (ABSL-3)
laboratories for at least 2 weeks before infection with
Mycobacterium tuberculosis.
The Mycobacterium tuberculosis strain used was Erd-
man (TMC 107, ATCC 35801). The strain was grown
initially as a pellicle as described previously by North &
Izzo [86] with the following modifications. Briefly, the
original vial was resuspended in Proskauer-Beck (PB)
media and cultured as a pellicle for three passages. The
final pellicle was harvested, disbursed into PB media
with Tween 80 (Sigma Chemical Co., St Louis, MO,
USA), and snap frozen after addition of glycerol (20 %
total) as 1 ml seed stock cultures. Working stocks (max-
imum of 3 passages) were expanded into either PB (for
infectivity stocks) or glycerol alanine salts (GAS) (for
large scale growth stocks) media to mid-log phase from
the seed stocks. Infectivity stock vials are recovered from
frozen storage prior to use in animal model studies.
P-MAPA was provided by Farmabrasilis (Farmabrasilis
fermentation pilot plant, Brazil) and 5 mg/kg of the
compound were administered via intraperitoneal injec-
tion in 1 X PBS (3 x per week). Moxifloxacin (MXF)
was administered daily at 50 mg/kg, by oral gavage,
5 days per week (at 0.2 ml per mouse) [87]. MXF was
prepared in water. Organ harvesting was done at least
48 hours after last drug administration for the group
to allow for clearance of the drugs prior to harvest
of organs.
Written consent was obtained for all animal studies
after institutional review and approval by the Animal Care
and Use Committee at the Colorado State University. Six-
to 8-week-old female specific pathogen-free immunocom-
petent C57BL/6 mice (Charles River, Wilmington, MA)
were infected via a low dose aerosol exposure to Myco-
bacterium tuberculosis Erdman in the Animal Biosafety
Level-3 Laboratories (ABSL3), as described by Kelly et al.
[88]. Three mice were euthanized one day post low dose
aerosol to verify bacterial uptake of 50 to 100 CFU per
mouse. Treatment was started 3 weeks post-infection and
continued for 4 weeks. Five infected mice were eutha-
nized at the start of treatment as pretreatment controls.
Mice were euthanized by CO2 inhalation 4 weeks after
the start of treatment.
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plates, the left lung lobes were aseptically removed and
disrupted in a tissue homogenizer as previously
described by Lenaerts et al. [87]. The number of viable
organisms was determined by plating serial dilutions of
the homogenates on nutrient Middlebrook 7 H11 agar
plates (GIBCO BRL, Gaithersburg, MD). The plates were
incubated at 37 °C in ambient air for 4 weeks prior to the
counting of viable Mycobacterium tuberculosis colony
forming units (CFU).
The antimycobacterial activity analyses were expressed
as the log10 (and as log10 reduction) provided by a
given dose of the MXF, P-MAPA and MXF+P-MAPA
against the growth of the Mycobacterium tuberculosis in
the untreated control group. Compounds with log10
protection factors> 0.60 were considered active [87].
Experimental design in Bladder Cancer
Sixty 7-week-old female Fisher 344 rats were obtained
from the Multidisciplinary Center for Biological Investi-
gation (CEMIB) at University of Campinas (UNICAMP).
Forty-five animals were anesthetized with 10 % keta-
mine (60 mg/kg, i.m.; VibraW Roseira, São Paulo, Brazil)
and 2 % xylazine (5 mg/kg, i.m.; VibraW Roseira, São
Paulo, Brazil) and received 1.5 mg/Kg dose of n-methyl-
n-nitrosourea (MNU) dissolved in 0.30 mL of sodium
citrate (1 M pH 6.0); through a 22-gauge angiocatheter
intravesically every other week for 8 weeks [26] The ani-
mals remained anesthetized for approximately 45 min-
utes after catheterization to prevent spontaneous
micturition. The other 15 animals (Control group)
received 0.30 ml dose of 0.9 % physiological saline, intra-
vesically every other week for 7 weeks After MNU treat-
ment, the 60 rats were divided into 4 groups (15 animals
per group): The Control (CT) group received 0.30 ml
dose of 0.9 % physiological saline intravesically every
other week for 8 weeks; The MNU group (Bladder Can-
cer) received the same treatment as the CT group; The
BCG group received 106 CFU (40 mg) dose of BCG intra-
vesically every other week for 8 weeks; The P-MAPA
group received 5 mg/kg dose of P-MAPA (Farmabrasilis,
Campinas, SP, Brazil) intravesically every other week for
8 weeks.
After 16 weeks of treatment, all animals were submit-
ted to cystography to evaluate the occurrence of tumor.
After that, the rats were euthanized and urinary bladder
was collected, processed for histopathological and West-
ern Blotting analysis. All protocols involving animal
care and use were approved by the Institutional Com-
mittee for Ethics in Animal Experimentation (CEUA/IB/
UNICAMP – 2684–1).
For histopathological analysis, urinary bladders were
randomly collected from 10 animals in each group, fixed
by immersion in 4 % paraformaldehyde, embedded inparaffin, cut into 5-μm thick and stained with
hematoxylin-eosin. The neoplastic lesions were diag-
nosed using the nomenclature proposed by the World
Health Organization/International Society of Urological
Pathology consensus classification [89].Western Blotting Analysis of TLR2, TLR4 and p53
Urinary bladders were randomly collected from 5
animals in each group, frozen in liquid nitrogen,
weighed and homogenized in 50 μl/mg of lysis buffer.
The tissue homogenates were centrifuged and a sample
of each extract was used for protein quantification by
Bradford`s method. Aliquots containing 50–70 μg of
protein were separated by SDS-PAGE on 12 % polyacryl-
amide gels under reducing conditions. After electrophor-
esis, the proteins were transferred to Hybond-ECL
nitrocellulose membranes (Amersham, Pharmacia Bio-
tech, Arlington Heights, IL., USA). The membranes were
blocked with TBS-T containing 1 % BSA (bovine serum
albumin) and incubated at 4 °C overnight with primary
rabbit polyclonal antibody ab13855 (abcam, USA) for
the TLR2, mouse monoclonal ab30667 (abcam, USA) for
the TLR4 and mouse monoclonal ab26 (abcam, USA)
for the p53 (diluted 1:2,000; 1:2,000 and 1:1,500, respect-
ively in 1 % BSA). The membranes were then incubated
for 2 h with rabbit or mouse secondary HRP-conjugated
antibodies (diluted 1:3,000 in 1 % BSA; Santa Cruz Bio-
technology, Santa Cruz, CA, USA). Peroxidase activity
was detected with SuperSignal West Pico Chemilumin-
escent Substrate kit (Pierce Biotechnology, Rockford,
Illinois, USA). The luminescent signal from Western
blot bands was captured by a G:Box iChemi camera
(Syngene, Cambridge, UK) and band intensities were
quantified using the analysis software provided by
the manufacturer (Gene Tools Version 4.01, Syngene,
Cambridge, UK). The results were expressed as means
of ratio between each band intensity compared with
β-actin band intensity.Toxicological and Biochemical Analysis
In order to investigate possible hepatotoxic effects of
P-MAPA and BCG the following serum analyses were
carried out: activity of alanine aminotransferase (ALT),
a specific marker for hepatic parenchymal injury; aspar-
tate aminotransferase (AST), nonspecific markers for
hepatic and/or cardiac injury; as well as the circulating
levels of creatinine and urea in order to verify renal func-
tion. The alkaline phosphatase activity was verified to
BC progression. The spectrophotometric determinations
were performed in a Pharmacia Biotech spectrophotom-
eter with temperature-controlled cuvette chamber (UV/
visible Ultrospec 5,000 with Swift II applications software
to computer control, 97–4213, Cambridge, England,
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Statistical Analysis
The Western Blotting, human TLR ligand screening,
in vitro antimycobacterial activity and toxicological
and biochemical analyses were statistically compared
among the groups by analysis of variance followed by
the Turkey’s test, with the level of significance set at 1 %
and 5 %. The results were expressed as the mean ±
standard deviation.
For in vivo antimycobacterial activity analyses, the
CFU were converted to logarithms (log10CFU), which
were then evaluated by multiple comparison analyses of
variance including a one-way ANOVA test followed by a
two-way ANOVA. For early treatment data, an ANOVA
F-test was done to compare all treatments followed by
comparisons of specific pairs of means. When the log
counts were <2 logs and contained a large proportion
of zeros, the Wilcoxon Rank Sum test was used.
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